Literature DB >> 1993628

Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03.

L Tupchong1, C B Scott, P H Blitzer, V A Marcial, L D Lowry, J R Jacobs, J Stetz, L W Davis, J B Snow, R Chandler.   

Abstract

This is a report of a 10-year median follow-up of a randomized, prospective study investigating the optimal sequencing of radiation therapy (RT) in relation to surgery for operable advanced head and neck cancer. In May 1973, the Radiation Therapy Oncology Group (RTOG) began a Phase III study of preoperative radiation therapy (50.0 Gy) versus postoperative radiation therapy (60.0 Gy) for supraglottic larynx and hypopharynx primaries. Of 277 evaluable patients, duration of follow-up is 9-15 years, with 7.6% patients lost to follow-up before 7 years. Loco-regional control was significantly better for 141 postoperative radiation therapy patients than for 136 preoperative radiation therapy patients (p = 0.04), but absolute survival was not affected (p = 0.15). When the analysis was restricted to supraglottic larynx primaries (60 postoperative radiation therapy patients versus 58 preoperative radiation therapy patients), the difference for loco-regional control was highly significant (p = .007), but not for survival (p = 0.18). In considering only supraglottic larynx, 78% of loco-regional failures occurred in the first 2 years. Thirty-one percent (18/58) of preoperative patients failed locally within 2 years versus 18% (11/60) of postoperative patients. After 2 years, distant metastases and second primaries became the predominant failure pattern, especially in postoperative radiation therapy patients. This shift in the late failure pattern along with the increased number of unrelated deaths negated any advantage in absolute survival for postoperative radiation therapy patients. The rates of severe surgical and radiation therapy complications were similar between the two arms. Because of an increased incidence of late distant metastases and secondary primaries, additional therapeutic intervention is required beyond surgery and postoperative irradiation to impact significantly upon survival.

Entities:  

Mesh:

Year:  1991        PMID: 1993628     DOI: 10.1016/0360-3016(91)90133-o

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  28 in total

1.  Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

Authors:  A Chahlavi; T Todo; R L Martuza; S D Rabkin
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 2.  Management of cervical metastasis.

Authors:  Eric J Lentsch
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

Review 3.  Cancer of the oral cavity.

Authors:  Pablo H Montero; Snehal G Patel
Journal:  Surg Oncol Clin N Am       Date:  2015-04-15       Impact factor: 3.495

Review 4.  Transoral robotic surgery and a paradigm shift in the management of oropharyngeal squamous cell carcinoma.

Authors:  Harry Quon; Bert W O'Malley; Gregory S Weinstein
Journal:  J Robot Surg       Date:  2010-06-29

5.  Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant Setting.

Authors:  Yangyang Hu; Lin Lu; Yang Xia; Xin Chen; Alfred E Chang; Robert E Hollingsworth; Elaine Hurt; John Owen; Jeffrey S Moyer; Mark E P Prince; Fu Dai; Yangyi Bao; Yi Wang; Joel Whitfield; Jian-Chuan Xia; Shiang Huang; Max S Wicha; Qiao Li
Journal:  Cancer Res       Date:  2016-06-20       Impact factor: 12.701

Review 6.  Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives.

Authors:  Ari J Rosenberg; Everett E Vokes
Journal:  Oncologist       Date:  2020-09-21

7.  Organ function and quality of life after transoral laser microsurgery and adjuvant radiotherapy for locally advanced laryngeal cancer.

Authors:  Arno Olthoff; Andreas Ewen; Hendrik Andreas Wolff; Robert Michael Hermann; Hilke Vorwerk; Andrea Hille; Ralph Rödel; Clemens F Hess; Wolfgang Steiner; Olivier Pradier; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

Review 8.  Locally advanced head and neck cancer.

Authors:  M S Kies; C L Bennett; E E Vokes
Journal:  Curr Treat Options Oncol       Date:  2001-02

9.  Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.

Authors:  Paul M Harari; Jonathan Harris; Merrill S Kies; Jeffrey N Myers; Richard C Jordan; Maura L Gillison; Robert L Foote; Mitchell Machtay; Marvin Rotman; Deepak Khuntia; William Straube; Qiang Zhang; Kian Ang
Journal:  J Clin Oncol       Date:  2014-07-07       Impact factor: 44.544

Review 10.  Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck.

Authors:  C Ko; D Citrin
Journal:  Oral Dis       Date:  2008-11-11       Impact factor: 3.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.